Theravance Biopharma (STU:0TB) Debt-to-Revenue : 0.83 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Theravance Biopharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Theravance Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €3.74 Mil. Theravance Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €40.33 Mil. Theravance Biopharma's annualized Revenue for the quarter that ended in Mar. 2024 was €53.37 Mil. Theravance Biopharma's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.83.

Theravance Biopharma Debt-to-Revenue Historical Data

The historical data trend for Theravance Biopharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma Debt-to-Revenue Chart

Theravance Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

6.95

9.41

12.11

1.02

0.86

Theravance Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial															1.23	0.94	0.81	0.70	0.83

Competitive Comparison of Theravance Biopharma's Debt-to-Revenue

For the Biotechnology subindustry, Theravance Biopharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theravance Biopharma's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's Debt-to-Revenue falls into.

Theravance Biopharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Theravance Biopharma's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3.597	+	41.481)	/	52.658
	=	0.86

Theravance Biopharma's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3.738	+	40.333)	/	53.372
	=	0.83

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Theravance Biopharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Theravance Biopharma (STU:0TB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (STU:0TB) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

TBPH:USA 0TB:Germany

Address

Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104

Website

https://www.theravance.com

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Theravance Biopharma (STU:0TB) Headlines

No Headlines